Here, we report the identification of a second ARPKD-associated locus, which was found to contain homozygous mutations in the ciliarelated gene DZIP1L in seven patients from four families. We further validated these findings in mouse and zebrafish models. We show that DZIP1L localizes to centrioles and at the distal end of the basal body and interacts with septin2 (SEPT2), a protein involved in maintenance of the diffusion barrier at the transition zone. In agreement with these data, we found that in DZIP1L-deficient primary cilia, PC1 and PC2 showed altered distribution along the ciliary membrane.
RESULTS

DZIP1L is a new ARPKD-associated gene
In two unrelated consanguineous multiplex pedigrees (B16 and A3533) including a total of five children affected by ARPKD, mutations in known PKD-associated genes were excluded by linkage analysis and sequencing ( Fig. 1 and data not shown) . Genome-wide SNP analysis in DNA from parents and all affected children revealed a single overlapping homozygous peak, thus suggesting a new disease locus on chromosome 3q22.1-q23, in a 7.5-Mb region of genomic DNA ( Fig. 1) . Through whole-exome sequencing (WES) and subsequent Sanger sequencing, we identified different homozygous missense DZIP1L mutations that segregated with disease in each family (family B16, c.269C>T (p.Ala90Val); family A3533, c.273G>C (p.Gln91His); NM_173543.2) (Fig. 1, Supplementary Fig. 1 and Supplementary Table 1) . Interestingly, these mutations affect adjacent evolutionarily conserved residues of DZIP1L and were bioinformatically predicted to be pathogenic ( Table 1) . No further convincing variants were identified in the candidate region in these pedigrees. All three affected individuals in family B16 showed enlarged polycystic kidneys with decreased corticomedullary differentiation, and all developed arterial hypertension early during childhood. A comparable clinical course was observed in the two affected girls in family A3533 (Table 1) .
Next, we analyzed DZIP1L by Sanger sequencing in 218 unrelated subjects with suspected ARPKD or sporadic PKD, most of whom had tested negative for mutations in known cystoproteinencoding genes. A further 1,330 subjects with a PKD phenotype (n = 525) or a nephronopthisis (NPHP)-related complex ciliopathy (n = 805) were analyzed by next-generation sequencing (NGS), primarily targeted multigene panel testing 16 . Thereby, we identified different homozygous protein-truncating DZIP1L mutations (c.463C>T (p.Gln155*) and c.1061_1062del (p.Glu354Alafs*39)) in two additional unrelated consanguineous pedigrees, B155 and B8031, which had hallmarks of ARPKD (Fig. 1, Table 1 and Supplementary Fig. 1 ).
DZIP1L encodes a 767-amino acid protein containing a C2H2-type zinc-finger motif (amino acids 166-189) and a series of coiled-coil domains (amino acids 205-406) ( Supplementary Fig. 2 ), and previous overexpression studies have shown its localization to the ciliary base 17 . In zebrafish and mice, we and others have implicated the paralog Dzip1 in hedgehog (HH) signaling and ciliogenesis [18] [19] [20] [21] [22] , but little is known regarding Dzip1l function in any organism. Mapping of a new ARPKD locus on 3q22.1-q23 and identification of DZIP1L mutations. Genome-wide SNP analysis performed in two unrelated consanguineous multiplex pedigrees (top) with a total of five children affected by ARPKD resulted in identification of a single overlapping 7.5-Mb region of homozygosity on chromosome 3q22.1-q23. Through various sequencing approaches, we identified different homozygous DZIP1L mutations in these and other consanguineous families with ARPKD (details in main text). In parallel, we identified an ENU-induced recessive mouse model (Fig. 2) bearing the homozygous Dzip1l nonsense mutation c.1123C>T (p.Gln375*) (in blue). 
A Dzip1l loss-of-function mouse model
In a recessive N-ethyl-N-nitrosourea (ENU) mutagenesis screen 23 , we identified a mouse mutant (warpy or wpy) with widespread embryonic dysmorphologies. Linkage analysis mapped the mutation to a 64-Mb region on chromosome 9, and subsequent WES identified eight homozygous mutations, only one of which, a nonsense mutation in the region encoding the coiled-coil domains of Dzip1l (c.1123C>T (p.Gln375*); NM_028258.4), was within the linkage interval ( Supplementary  Fig. 3a and Online Methods). On a C57BL/6; C3H mixed or a pure C57BL/6 background, homozygous Dzip1l wpy/wpy mutants displayed a range of phenotypes, including highly penetrant polydactyly of all four limbs as well as craniofacial defects (Fig. 2) , including full or partial cleft palate and bilateral cleft lip ( Fig. 2f-k) .
Gross eye abnormalities were evident in 67% (n = 30/45) of embryos scored from 13.5 days postcoitum (dpc) onward and, in some cases, eyes were internalized (Fig. 2j,k) . Homozygous C57BL/6;C3H mutant embryos were recovered at approximately the expected mendelian frequency at midgestation (23.3% at 10.5 dpc, n = 66/283), but, although some embryos were recovered up to 18.5 dpc, viability was decreased at later stages. These phenotypes, particularly polydactyly, suggested a defect in HH signaling, a pathway regulated by the primary cilium 24 . Accordingly, through whole-mount in situ hybridization, we observed expansion of Hoxd13 and gremlin (Grem1) expression in the anterior fore-and hindlimb buds of 11.5-dpc Dzip1l wpy/wpy embryos (n = 3 embryos; Supplementary Fig. 3b ; hindlimb data not shown), thus suggesting a decrease in the repressor form of the GLI3 transcription factor, which mediates HH signaling in the limb 25 . In agreement with cilia and GLI3 regulating HH signaling downstream of ligand, the expression of sonic hedgehog (Shh) appeared unaltered in mutant limbs. Interestingly, whereas patched1 (Ptch1) was not consistently altered, another universal downstream marker of HH signaling, Gli1, showed subtle but consistent ectopic anterior expression (Supplementary Fig. 3b ). We next assessed the ability of Dzip1l wpy/wpy mouse embryonic fibroblasts (MEFs) to respond to the HH agonist SAG, and we observed an attenuated response relative to that of wildtype MEFs, as measured by qRT-PCR for Gli1 (Supplementary Fig. 3d ). In contrast to the results for the limb and MEFs, we saw no evidence of altered HH signaling across the dorsal-ventral axis of the neural tube in Dzip1l wpy/wpy embryos, as assessed by staining for markers of SHH-dependent neuronalA r t i c l e s populations, regardless of the anterior-posterior level of the sections (n = 2 embryos for Shh; n = 3 embryos for other markers; Supplementary Fig. 3c ). Our data suggested tissue-specific effects on HH signaling in Dzip1l wpy/wpy embryos, with gene expression changes in the limb consistent with polydactyly.
Dzip1l wpy/wpy mutants develop cystic kidney disease
On a mixed C57BL/6;C3H background, Dzip1l wpy/wpy embryos displayed cystic kidneys from 15.5 dpc (data not shown). To analyze the postnatal progression of this phenotype, we crossed the mice to an outbred CD1 background, and after four generations, we were able to recover live mice. These mice still displayed limb defects, although the defects were less severe than those in the inbred embryos; however, gross facial-clefting phenotypes were rare. These results suggested that some of the dysmorphologies seen in the Dzip1l wpy/wpy embryos, but not in people with ARPKD, may have been due to genetic background effects. Homozygous mutants were born at the expected mendelian frequency (25.2%, n = 30/119) but showed a general failure to thrive, and all were sacrificed no later than postnatal day (P) 21.
Histological analysis of kidney sections after at least four crosses to CD1 revealed a highly penetrant progressive cystic-kidney phenotype in Dzip1l wpy/wpy mice (Fig. 3) . Late in embryogenesis, the most prominent cysts were located toward the renal cortex ( Fig. 3a,b ; n = 4 embryos for 15.5 dpc). At P0 (n = 6 mice), throughout the medullary region, we observed marked dilatations that stained positive for the collecting-duct marker Aquaporin2 (Aqp2) (Fig. 3c-f,h,j) . Some more cortical cysts stained positive for a proximal-tubule marker (LTL-biotin) (Fig. 3e,f,i) . The phenotype increased in severity with age, and P21 kidneys were massively cystic and larger than those of the wild type after correction for body weight ( Fig. 3k-m . Scanning electron micrographs of 15.5-dpc embryo heads, shown with the lower jaw removed in f and g (n = 2); 13.5-dpc embryo heads in h and i (n = 3). (j,k) In a subset of Dzip1l wpy/wpy embryos (n = 30/45 scored) the eyes appeared visibly abnormal, and in severe cases, analysis of H&E-stained frontal sections showed eyes buried within the head (arrow in k; n = 2/5 embryo heads sectioned at >13.5 dpc; 15.5-dpc embryo heads shown). The control embryos shown in b, f and j were heterozygous and showed no obvious phenotypic differences as compared with wild-type controls, as shown in a, d and h. The limbs shown in d and e are from different embryos from those in b and c. Scale bars: a-c, 2 mm; d,e, 0.5 mm; f-k, 1 mm. All data presented are from embryos on a C57BL/6;C3H mixed background. (n-q) H&E staining of P21 liver sections. Arrows mark an excess of bile ducts, which nearly circumferentially surround portal-vein branches in P21 Dzip1l wpy/wpy -mutant (o,q) compared with wild-type (n,p) mice, thus indicating DPM (n = 2 mice). Scale bars: a,b, 100 µm; c-f, 200 µm; k,l, 500 µm; g-j and n-q, 50 µm.
( Fig. 3n-q and Supplementary Fig. 4 ). Hepatic fibrosis was not detected, probably because of the young age of these mice.
Inactivation of zebrafish dzip1l causes phenotypes consistent with ciliary dysfunction
The single ortholog of DZIP1L in the zebrafish genome (NM_001037227.1; Supplementary Fig. 2 ) is maternally expressed (Supplementary Fig. 5a ), and embryos at 1 day postfertilization (dpf) expressed fairly ubiquitous but low levels of dzip1l, with a more discrete accumulation in the embryonic kidneys-the pronephric ducts ( Supplementary Fig. 6a,b) . Unlike the solitary primary cilium in mammalian kidney cells, zebrafish pronephric-duct cells contain motile cilia, and the midsection of each duct contains cells bearing monomotile cilia interspersed with multiciliated cells (MCCs). dzip1l expression was observed in the midsections of the pronephric ducts, in a pattern consistent with the MCCs (magenta) and DZIP1L (cyan) colocalize at the transition zone in human dermal fibroblasts. ARL13B-GFP was used to mark the ciliary membrane around the axoneme (green in j). (k) 3D-SIM super-resolution microscopy on RPE-1 (human retinal pigment epithelial) cells confirms that both DZIP1L (cyan) and TCTN1 (magenta) are closely associated at the transition zone. Cilia are labeled with ARL13B-GFP (green). Nuclei are stained with DAPI (blue). Scale bars: a-i, 5 µm; j, 1 µm; k, 500 nm. DZIP1L was stained with Sigma C-terminal antibody, except in c, d, j and k, in which the Abnova antibody was used.
A r t i c l e s (Supplementary Fig. 6b) , and in the nasal placodes, another tissue populated by MCCs (Supplementary Fig. 6c ).
We next used four different antisense morpholino oligonucleotides (one translation blocking and three splice inhibitory) to knock down dzip1l function; all four produced largely identical cilia-related phenotypes. From 2 dpf onward, dzip1l morphants presented a slight bodyaxis curvature, hydrocephalus and defects in otolith formation in the inner ear (Supplementary Fig. 6d-g ). Otolith defects were observed in 11-16% of translation-blocking (n = 243 embryos) and splice-inhibitory (n = 562 embryos) morpholino-injected embryos but not in controls (n = 195 embryos) (Supplementary Fig. 6e,g,i) . Despite the ciliarydysfunction phenotypes, no obvious alterations in HH signaling were detected in 1-or 2-dpf dzip1l-morphant embryos, on the basis of in situ hybridization for ptch2, eng1a and nkx2.2b expression (data not shown).
To investigate defects in glomerular and pronephric tubules, we injected the dzip1l translation-blocking morpholino into Tg(wt1b:: GFP) transgenic embryos expressing GFP in the pronephros 26 . Approximately 10% of morphant embryos displayed glomerular cysts (n = 1,158 embryos) ( Supplementary Fig. 6h,i) . The specificity of the dzip1l-morphant phenotypes was demonstrated by co-injection of embryos with the translation-blocking morpholino and wild-type dzip1l mRNA. 85% of the morphants showed severe morphological defects, compared with 35% of the mRNA-co-injected embryos (n = 463 embryos and n = 313 embryos, respectively) ( Supplementary  Fig. 6j ). mRNA rescue was confirmed with a second (splice-blocking) morpholino (data not shown). RT-PCR analysis confirmed mis-splicing ( Supplementary Fig. 5b-d) .
We next generated a mutant dzip1l allele by using CRISPR-Cas9 technology, targeting exons 2 and 13 with two separate guide RNAs to induce a large deletion (Supplementary Fig. 5e,f) . Embryos homozygous for this deletion showed highly penetrant defects in otolith deposition but no additional morphological abnormalities (Supplementary Fig. 5g ). Because dzip1l is maternally expressed, we raised zygotic mutants to adulthood and bred them to obtain maternal-zygotic-mutant embryos. Like the zygotic mutants, maternal-zygotic dzip1l-deficient embryos exhibited defective otolith deposition but no other overt morphological changes (data not shown).
DZIP1L localizes to centrioles and to the distal ends of basal bodies
To investigate the subcellular localization of endogenous DZIP1L, we used two commercial antibodies: one raised against the C terminus of DZIP1L (Sigma-Aldrich) and one raised against the entire protein (Abnova). Both antibodies stained centrioles and basal bodies in mouse kidney inner-medullary collecting duct (IMCD3) cells, MEFs and human dermal fibroblasts (Fig. 4a-i, Supplementary Fig. 7a ,c,f and data not shown). Furthermore, DZIP1L remained localized to the centrioles throughout the cell cycle, even when cilia were disassembled during mitosis (Fig. 4e-i) . The mother centriole, from which the basal body is derived, acquires subdistal and distal appendages, and distal appendages or transition fibers anchor the basal body to the ciliary membrane at the transition zone 27 . DZIP1L staining overlapped with both subdistal (ODF2) and distal (CEP164) appendage markers in IMCD3 cells (Fig. 4c,d) , thus suggesting that DZIP1L localizes to the distal end of the mother centriole, possibly at the site where the transition zone forms. In agreement with this finding, DZIP1L colocalized with the transition-zone protein tectonic1 (TCTN1) in ciliated human fibroblasts (Fig. 4j) . This result was confirmed in retinal pigment epithelium (RPE-1) cells by super-resolution microscopy (3D-SIM), which improved resolution (by a factor of two in all dimensions, thus yielding ~120-nm resolution laterally, x,y) and revealed that DZIP1L and TCTN1 indeed localized near to each other (Fig. 4k) .
As expected, the antibody to C-terminal DZIP1L (Sigma-Aldrich) did not detect specific staining in mutant Dzip1l wpy/wpy MEFs or human fibroblasts from patient B155 (p.Gln155*), both of which contain protein-truncating mutations (Supplementary Fig. 7a,b,f,g ). However, some residual staining was detected with the Abnova antibody raised against the entire DZIP1L protein, in both mutant cell types (Supplementary Fig. 7c,d and data not shown). In further support of these results, qRT-PCR showed decreased but present Dzip1l expression in Dzip1l wpy/wpy MEFs, with no compensatory change in Dzip1 (Supplementary Fig. 7e) . Immunoblotting with the Abnova antibody revealed a band at the predicted size of DZIP1L in control but not B155 human cells, thereby confirming a lack of full-length protein in mutant cells (Supplementary Fig. 7h ). Although we cannot rule out the possibility that the truncated mouse and human DZIP1L proteins might retain some function, both would substantially lack known functional domains.
Cilia number is largely unaffected in Dzip1l-mutant tissue
In early-passage cultures, serum-starved B155 mutant human fibroblasts, as compared with controls, displayed no obvious differences in the percentage of ciliated cells, cilia morphology or localization of several markers of cilia and basal bodies (ARL13B, acetylated-α-tubulin, CEP164, DZIP1 and TCTN1; data not shown). However, in MEFs, we consistently observed a decrease in the percentage of ciliated cells in serum-starved Dzip1l wpy/wpy cells compared with control cultures (Supplementary Fig. 8a) . Interestingly, in a number of embryonic mouse tissues, including the limb-bud mesenchyme, we observed no differences in the relative proportion of cilia between mutant and wild-type embryos (n = 3 embryos; Supplementary Fig. 8b ). The only location in which we found evidence of fewer cilia was in the collecting-duct dilatations in the Dzip1l wpy/wpy kidney (data not shown), but this result was probably a consequence of the dilatations rather than a cause. We also saw no obvious primary-cilia defects in dzip1l-deficient zebrafish embryos (Fig. 5a,b and data not shown). However, in agreement with the prominent expression of dzip1l in MCCs in kidney tubules, numbers of cilia bundles were consistently decreased in morphant and zygotic and maternal-zygotic dzip1l-mutant embryos (Fig. 5c-e and data not shown).
DZIP1L associates with the ciliary-transition-zone protein SEPT2
To further explore the function of DZIP1L at cilia, we used human DZIP1L as bait to screen for interacting proteins in yeast two-hybrid libraries of highly ciliated human tissues (testis, lung and brain). From all three libraries, SEPT2 was identified as a high-confidence interactor with DZIP1L (Supplementary Table 2) . Septins are cytoskeletal GTPases, and SEPT2 functions as part of the periciliary diffusion barrier at the transition zone 28, 29 . The interaction was verified by coimmunoprecipitation of epitope-tagged DZIP1L and SEPT2 (Fig. 6a) from transfected HEK293T cells (Fig. 6b) and by coimmunoprecipitation of the endogenous proteins from RPE-1 cells (Fig. 6c-e) . Moreover, immunostaining of human dermal fibroblasts showed colocalization of DZIP1L and SEPT2 at the ciliary base (Fig. 6f) . In support of the specificity of the interaction, we did not detect interaction in coimmunoprecipitation experiments between transfected SEPT2 and several other transition-zone (NPHP1, MKS1 and B9D1) and basal-body appendage (CEP89) proteins. Likewise, we did not detect any interaction between these proteins and DZIP1L (Supplementary Fig. 9 ).
To localize the domains in DZIP1L that interact with SEPT2, we generated a series of epitope-tagged N-and C-terminal-deletion DZIP1L constructs and tested their ability to associate with SEPT2 in coimmunoprecipitation assays (Fig. 6a) . We found that all proteins, except a C-terminal fragment (from amino acid 500 to the end of the protein), interacted with SEPT2 (Fig. 6b) . Intriguingly, even a small fragment consisting of the N-terminal 165 amino acids and lacking the zinc-finger and the coiled-coil domains (thus effectively mimicking the predicted truncation of DZIP1L in patient B155), retained the ability to interact with SEPT2. This result may explain why we did not observe any alteration in SEPT2 localization at the transition zone in the B155 DZIP1L-mutant human fibroblasts (Fig. 6g,h) .
Loss of DZIP1L affects the localization of PKD proteins to the ciliary membrane
The cystic kidney phenotype caused by loss of DZIP1L led us to investigate the ciliary localization of the two ADPKD-associated proteins PC1 and PC2 in DZIP1L-mutant cells. Using an N-terminal monoclonal antibody to PC1 (7e12) 30 (validation in Supplementary  Fig. 10 ), we found that in Dzip1l wpy/wpy ciliated MEFs, PC1 was often enriched at the proximal end of the axoneme, whereas in wildtype MEFs, PC1 staining was more frequently observed along the length of the axoneme (Fig. 7a-c) . In control human fibroblasts, we detected PC1 at the basal body and along the axoneme, whereas there was a decrease in PC1 accumulation along the ciliary membrane of fibroblasts from individual B155 (Fig. 7d-f) . PC2 ciliarymembrane localization was similarly affected in B155 fibroblasts (as detected with polyclonal antibody to amino acids 349-361; details in SEPT2-Flag U n t r a n s f e c t e 
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Online Methods and validation in Supplementary Figure 11 (Fig. 7g-i) .
These results suggested that in the absence of correct DZIP1L function, the ciliary-membrane distribution of PC1 and PC2 is compromised, thus possibly reflecting a defect in the barrier function of the transition zone. However, this defect is unlikely to be generalized, because the HH co-receptor smoothened (SMO) localized normally along the axoneme in response to SAG treatment in Dzip1l wpy/wpy MEFs (Supplementary Fig. 11 ). Although we also analyzed the localization of FPC in human fibroblasts, in our hands, two independent antibodies revealed prominent staining around the basal body, as described previously 8, 9 , but not along the axoneme. This pattern remained unaffected in cells from individual B155 (data not shown).
DISCUSSION
In clinical genetics, there is a strong demand for early and reliable diagnosis of ARPKD, which is feasible only through molecular genetic analysis. To date, PKHD1 has been thought to be the only gene associated with ARPKD. We identified DZIP1L mutations in ARPKD, thereby describing a second locus for this disease. Although the clinical manifestations in our patients were first detected prenatally or during early childhood, none of our patients had perinatal demise, which affects approximately 30% of ARPKD patients with PKHD1 mutations 31, 32 . Mutations in DZIP1L are a considerably rarer cause of ARPKD than PKHD1 mutations, possibly in part because of the larger size of PKHD1 relative to DZIP1L. Furthermore, our limited data suggested that the region encoding the N terminus of DZIP1L may be more susceptible to mutations, a concept supported by in silico data that predicted pathogenicity scores to decay toward the C terminus (Supplementary Fig. 12 ). Although we have not screened large numbers of embryonic-lethal patients, in view of the homozygous truncating mutations in two of our patients, we hypothesize that it is unlikely that DZIP1L mutations play a major role in this cohort. This conclusion is consistent with the birth of homozygous-mutant outbred mice at expected frequencies. Despite the relatively rare occurrence of pathogenic DZIP1L mutations, ARPKD NGS diagnostic multigene panels should nevertheless target this gene. Ultrasonographic patterns observed in our patients mimicked the phenotype of PKHD1-linked ARPKD, including characteristic bilaterally enlarged, echogenic kidneys, poor corticomedullary differentiation and multiple small cysts. Macrocysts are uncommon in infants, although they may be present with advanced clinical course. Renal failure is rarely a cause of neonatal demise in ARPKD, but renal function variably deteriorates over time. Most of our patients developed chronic renal failure when they were of school age; end-stage renal disease (ESRD) occurred in four patients. However, most patients were younger than 20 years at the time of analysis, and the remaining may develop ESRD later in life. For PKHD1-linked ARPKD, 25% of nonperinatal patients require kidney transplantation by age 32 (ref. 33) . Most of our patients developed arterial hypertension in their first years of life, as is typical in ARPKD. DPM with congenital hepatic fibrosis is another hallmark of ARPKD. We detected subtle early signs of DPM in Dzip1l wpy/wpy mice but did not observe more severe liver pathology, including hepatic fibrosis, probably because of the early demise of these mice. We can only speculate from our findings in mice that hepatic defects might also be present in our patients.
Dzip1l wpy/wpy -mutant mice displayed an early-onset, progressive cystic kidney phenotype, with cysts arising from the collecting ducts and proximal tubules. While ARPKD usually affects the collecting ducts and distal tubules, individuals may exhibit involvement of other nephron segments, including proximal tubules (ref. 34 and C.B., unpublished data). Moreover, a number of Pkhd1 mouse models display proximal-tubule cysts, although the phenotype in mice carrying different alleles of Pkhd1 is variable, and kidney involvement generally manifests later in these mice than in Dzip1l wpy/wpy mice [35] [36] [37] .
Unlike patients with DZIP1L mutations, Dzip1l wpy/wpy mouse embryos displayed a number of extrarenal dysmorphologies including limb and craniofacial defects. The amelioration of craniofacial phenotypes after crossing to an outbred background suggested that at least some of these differences may be due to genetic background, and indeed many ciliary-related phenotypes are subject to variation, on the basis of genetic modification of alleles 38 . Phenotypic differences between human and mouse models are sometimes observed. For example, nonrenal and hepatobiliary phenotypes have been reported in PKD mouse models, including craniofacial, cardiovascular and skeletal defects in homozygous Pkd1-mutant mice 39, 40 . Although we cannot exclude the involvement of DZIP1L mutations in syndromic ciliopathies, pathogenic mutations have not been reported in large cohorts of ciliopathy patients screened to date. However, our data suggest the possibility that variation at DZIP1L may genetically interact with other PKD or ciliopathy loci in modifying phenotype. Our zebrafish analysis also supported a role of Dzip1l in the kidney, and we observed fewer motile cilia in dzip1l-deficient pronephric tubules. Although the mammalian kidney is populated by primary cilia, this result nevertheless suggests a conserved requirement of Dzip1l at cilia for proper kidney function across vertebrates. Notably, although dzip1l-morphant and mutant embryos exhibited overlapping phenotypes (for example, otolith and motile-cilia defects), we did not observe body curvature and hydrocephalus in either zygotic or maternal-zygotic mutants. These effects may have been morpholino-induced artifacts. However, because all four morpholinos produced these phenotypes, it is possible that some degree of genetic compensation was operating in the mutants, as has recently been described 41, 42 .
Our data suggested context-or tissue-specific roles of DZIP1L in primary ciliogenesis and HH signaling in the mice, whereas loss of the protein in zebrafish had milder effects on these processes. Previous studies in cultured human cells have suggested a redundant role of DZIP1 and DZIP1L in ciliogenesis 17 , a conclusion supported by our zebrafish in vivo experiments (data not shown). DZIP1 localizes to the basal body, the transition zone and the mother centriole 22, 43 . Our findings revealed a similar localization pattern for DZIP1L, and proteomic studies in Chlamydomonas reinhardtii have further suggested that DZIP1L is a transition-zone protein 44 . There is some debate as to the precise boundaries among the basal body, transition zone and axoneme 6 , and some proteins shuttle between these structures. In support of transition-zone localization, we found that DZIP1L associates with SEPT2, a component of the transition-zone diffusion barrier. Although DZIP1L has not been rigorously associated with any of the known transition-zone protein complexes, a recent mass spectroscopy study has included DZIP1L among an extensive list of proteins pulled down by Inturned, a core component of the CPLANE transition-zone complex that recruits a subset of intraflagellar transport A proteins to basal bodies 45 . Although this result indicates that DZIP1L may act in the CPLANE complex, further detailed analysis is required.
In agreement with a role of DZIP1L at the transition zone, the ADPKD-associated proteins PC1 and PC2 showed altered distribution along the ciliary membrane in the absence of correct DZIP1L function. In the renal tubules, PC1 and PC2 act in a ciliary-membrane complex, and FPC has been shown to bind and regulate PC2 (ref. 12). However, we were not able to detect FPC along the ciliary axoneme to determine whether this localization was also compromised by loss of DZIP1L function. In terms of how ciliary mislocalization of the polycystins may contribute to PKD, it has been proposed that the PC1/2 complex suppresses a yet-unidentified cilia-dependent cyst-formation signal that is inappropriately activated when the PC1/2 complex is unable to properly traffic to cilia 46 . Whether mislocalization of the polycystins is a major factor contributing to PKD in DZIP1L-mutant mice and humans remains to be determined. Nevertheless, our data demonstrate DZIP1L dysfunction as a new cause of ARPKD and extend understanding of the genetic heterogeneity underlying the pathology of this disorder.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Ethics approval. Human blood samples for DNA extraction and fibroblasts were obtained after subjects provided written informed consent. All investigations were conducted according to the Declaration of Helsinki, and the study was approved by the Institutional Review Boards of the Ethics Committee of the University Freiburg, University of Aachen, the University of Michigan, Boston Children`s Hospital and collaborating institutions. All mouse experimentation was performed under approval from the Institutional Review Board of the Australian National University and the animal ethics committee of The University of Queensland, and conformed to ethical guidelines. All experiments involving zebrafish were approved by the animal committees of the relevant institutes (Regierungspräsidium Baden-Württemberg and the Singapore National Advisory Committee on Laboratory Animal Research).
Human haplotype analysis and SNP genome-wide linkage analysis (homozygosity mapping). Initially, linkage to PKHD1 was excluded through haplotype analysis. Two informative flanking markers were typed in our index pedigree B16. DNA samples were available from parents and all affected individuals. Primers for PCR amplification were as previously published and are available on request. Microsatellite markers were analyzed on an ABI PRISM 3130 genetic analyzer (Applied Biosystems). Subsequently, we performed genome-wide SNP mapping in the above first-degree consanguineous index family with three affected children (LOD score 2.4; Fig. 1 ) and family A3533, as reported previously 47 . DZIP1L mutation analysis. Mutation analysis was done by direct sequencing of the 15 exons encoding the 767-amino acid DZIP1L protein (GenBank, NM_173543.2 and NP_775814; mutation numbering corresponds to the A of the ATG translation-initiation codon in exon 2). Genomic DNA from an affected individual was amplified by PCR with oligonucleotide primers complementary to flanking intronic sequences. Primers used for PCR and direct sequencing are available on request. Samples were run and analyzed on an ABI PRISM 3130 genetic analyzer (Applied Biosystems).
In addition to conventional Sanger sequencing of DZIP1L in a total of 218 patients with suspected PKD, we performed different next-generation sequencing (NGS)-based approaches. First, we used PCR-based 48.48 Access Array microfluidic technology (Fluidigm) with consecutive NGS. We applied a multiplexing approach allowing PCR-based amplification of 53 amplicons (44 exons) for 48 DNA samples simultaneously in one known and two candidate genes, including DZIP1L. A total of 96 patients with a PKD-related phenotype were analyzed. After two rounds of amplification followed by indexing of all patient-derived products with 96 different 10-bp barcodes in a subsequent PCR, 2 × 150 bidirectional sequencing was performed on an Illumina MiSeq platform. Second, all exons and adjacent intronic boundaries of a different number of genes (dependent on the version of our customized multigene panel, including DZIP1L) known or hypothesized to cause PKD and other ciliopathies were targeted by a custom SeqCap EZ choice sequence capture library (NimbleGen) and subsequently sequenced on a Roche 454 GS FLX or an Illumina MiSeq or HiSeq platform (2 × 150 PE), according to the manufacturer's protocol. A total of 1,234 patients with a polycystic kidney disease phenotype (n = 429) or an NPHP-related complex ciliopathy (n = 805) were analyzed with an average coverage of 60 fold (GS FLX), 120 fold (MiSeq) or more than 200 fold (HiSeq), respectively. Bioinformatic analysis was performed with Roche GS Reference Mapper software (v2.6), the SeqPilot SeqNext module (v3.5.2, JSI medical systems) as well as an in-house bioinformatic pipeline. For all approaches, potential mutations were confirmed by Sanger sequencing and were shown to segregate with the phenotype. No further mutations thought to be of pathogenic relevance to the disease phenotype were present among the patients described in this manuscript. WES and mapping of reads was carried out as previously described 48, 49 .
Mouse strains and mutation detection. ENU mutagenesis screening was performed at the Australian Phenomics Facility (The John Curtin School of Medical Research, Australian National University), essentially as previously described 23 , except that C3H was used as the mapping strain. Phenotypic screening was performed at 14.5 dpc. The initial genome scan involved screening a pool of affected (C57BL/6 × C3H) F 2 mice and a pool of unaffected F 2 mice with a set of ~100 markers that were polymorphic between C57BL/6 and C3H mice and on average spanned the genome at 20-Mb intervals. The allele-specific SNP markers were designed with available software to amplify a subset of validated SNPs. SNP typing was performed with an Amplifluor kit (Chemicon). The individual DNA samples from each of the affected and unaffected F 2 individuals were run with markers that showed possible linkage to the mutation. Through this approach, the wpy mutation was mapped to a 64-Mb region on the mouse genome (GRCm38) on chromosome 9 between 48804027 (rs3023210) and 112866211 (rs3679771). In this interval there are >900 genes (GRCm38). Eight genes were chosen as potential candidates and subjected to Sanger sequencing of all candidate exons ±15 bp, with an Applied Biosystems 3730xl capillary sequencer using Big Dye Terminator (BDT) chemistry, version 3.1 (Applied Biosystems). The raw trace files were analyzed with Lasergene software (DNAstar) against the C57BL/6 mouse reference genome (NCBI). One mutation was identified in introns 19 to 20 of Kif9, 102 bp distal to exon 19 (T to C), but was unlikely to be causal. Subsequent whole-exome sequencing, as previously described 50 , was performed on samples enriched in exonic sequences by Nimblegen solution-based capture technologies, with an Illumina GAIIx system using 100-bp paired-end reads. This procedure resulted in the identification of eight homozygous mutations, of which only that in Dzip1l was located within the previously mapped critical interval. The mutation in Dzip1l was confirmed with affected and unaffected individuals from the mapping screen run, with an Amplifluor assay designed for the Dzip1l SNV, and also by Sanger sequencing at the Australian Genomic Research Facility. Subsequently, a PCR and restriction enzyme-based genotyping assay was developed (details available on request).
For detailed phenotypic analysis, C57BL/6;C3H mice were subsequently crossed with C57BL/6 wild-type mice through five generations (total of seven wild-type crosses from G 0 mutagenized founder), thus promoting removal of incidental ENU-induced mutations. A pure C57BL/6 line was also maintained through obtaining a frozen G 1 C57BL/6 individual and crossing through ten generations with wild-type C57BL/6 mice. The initial analysis of the Dzip1l wpy/wpy phenotype was performed on the C57BL/6;C3H mixed background with at least two backcrosses and was broadly consistent in subsequent generations and also on the C57BL/6 pure background in all generations. All data presented for the outbred CD1 background were obtained after at least four crosses to CD1 (in total, this line has now been crossed to CD1 through ten generations). On all background strains, the overall phenotype segregated with the Dzip1l mutation through all generations, and in more than 1,300 embryos and mice analyzed from heterozygous matings (amelioration of the craniofacial phenotypes was observed after crossing to a CD1 background). Wild-type littermates were used as controls in most cases, except when heterozygous embryos were used, as indicated. (Dzip1l wpy/+ heterozygous mice, as compared with wild type, displayed no discernible morphological differences.) Antibodies, stains and primers. The following primary antibodies were used: mouse anti-ARL13B and rabbit-anti-ARL13B (NeuroMab, clone N295B/66; 1:300 dilution for immunofluorescence (IF) and ProteinTech, 17711-1-AP; 1:500 for IF); rabbit-anti-α-tubulin (Sigma-Aldrich, T5192; 1:500 for IF); rabbit-anti-acetylated-α-tubulin (Cell Signaling Technology, 5335; 1:800 for IF); mouse-anti-acetylated-α-tubulin (Sigma-Aldrich, 6-11B-1; cat. no. T 6793; 1:500 to 1:700 for IF); mouse-anti-γ-tubulin (Sigma-Aldrich, T6557; 1:500 for IF), rabbit-anti-DZIP1L (Sigma-Aldrich, HPA030404; 1:500 for IF); mouseanti-DZIP1L (Abnova, MaxPab H00199221-B01P; 1:500 for IF; 1:1,000 for immunoblotting); rabbit-anti-DZIP1 (ProteinTech, 13779-1-AP; 1:500 for IF); rabbit-anti-SEPT2 (Sigma-Aldrich, HPA018481; 1:2,000 for immuno- 
